Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by askretkaon Mar 16, 2021 1:10am
273 Views
Post# 32805475

RE:RE:RE:RE:Checkpoint drugs' regulatory reckoning looms

RE:RE:RE:RE:Checkpoint drugs' regulatory reckoning looms
Yes the guy who is in charge at the FDA who has final approvals on cancer drugs is tough on drug companies because his wife died of ovarian cancer. He knows very well what patients go through on the many toxic chemo drugs. His name is at the end of my last post. Richard Pazdur. --------------------------- For nearly two decades, Richard Pazdur has been the countrys key figure in approving new cancer treatments. But when his own wife was diagnosed with the dreaded disease, his job took on a whole new meaning ---------------------- By Kristen Hannum ----------------- Richard Pazdur (MD '76) has been called the closest thing this country has to a cancer czar. As a leader in the Food and Drug Administrations oversight of oncology treatments, Pazdur has wielded great power and influence in approving or denying new drug therapies for cancer. In 2015, his work at the FDA even landed him onFortunemagazines list of the 50 greatest world leaders. But for Pazdur, 2015 will be remembered for a much more significant eventthe loss of his wife after a battle with ovarian cancer.
<< Previous
Bullboard Posts
Next >>